Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinson's Disease Dementia

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Jesse, Sarah ^a   Lehnert, Stefan ^a   Jahn, Olaf ^b,c   Parnetti, Lucilla ^d   Soininen, Hilkka ^e   Herukka, Sanna Kaisa ^e   Steinacker, Petra ^a   Tawfik, Saskia ^a   Tumani, Hayrettin ^a   von Arnim, Christine A F ^a   Neumann, Manuela ^f   Kretzschmar, Hans A ^g   Kulaksiz, Hasan ^a   Lenter, Martin ^h   Wiltfang, Jens ⁱ   Ferger, Boris ^h   Hengerer, Bastian ^h   Otto, Markus ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c Deutsche Forschungsgemeinschaft   (Germany)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF ZURICH   (Switzerland)

^g UNIVERSITY OF MUNICH   (Germany)

^h BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; SERPIN A1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PREDICTION; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; PROTEIN PROCESSING; SENSITIVITY AND SPECIFICITY; SIALYLATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ALPHA 1-ANTITRYPSIN; BIOLOGICAL MARKERS; BRAIN; DEMENTIA; HUMANS; PARKINSON DISEASE; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 84869022486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048783     Document Type: Article

References (58)

1. Di Napoli M, Shah IM, Stewart DA, (2007) Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev Neurother 7: 1693-1729.
2. Rongve A, Aarsland D, (2006) Management of Parkinson's disease dementia:practical considerations. Drugs Aging 23: 807-822.
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P, (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387-392.
4. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, et al. (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27: 349-356.
5. Aarsland D, Larson JP, Karlsen K, Lim NG, Tandberg E, (1999) Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14: 866-874.
6. Caballol N, Marti MJ, Tolosa E, (2007) Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22: 358-366.
7. Louis ED, Marder K, Cote L, Tang M, Mayeux R, (1997) Mortality from Parkinson disease. Arch Neurol 54: 260-264.
8. Singh B, O'Brien JT, (2009) When should drug treatment be started for people with dementia? Maturitas 62: 230-234.
9. Goedert M, Spillantini MG, (1998) Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 3: 462-465.
10. Jellinger KA, (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792: 730-740.
11. Jellinger KA, Attems J, (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115: 427-436.
12. Mukaetova-Ladinska EB, McKeith IG, (2006) Pathophysiology of synuclein aggregation in Lewy body disease. Mech Ageing Dev 127: 188-202.
13. Geser F, Wenning G, Poewe W, McKeith I, (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20Supplement 12: 11-20.
14. Andersson M, Zetterberg H, Minthon L, Blennow K, Londos E, (2011) The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 26: 100-105.
15. Kramer ML, Schulz-Schaeffer WJ, (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27: 1405-1410.
16. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, et al. (2004) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 279: 4625-4631.
17. Braak H, Braak E, (2000) Pathoanatomy of Parkinson's disease. J Neurol 247 (Suppl 2): II3-10.
18. Braak H, Rub U, Sandmann-Keil D, Gai WP, de Vos RA, et al. (2000) Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 99: 489-495.
19. Wolters ECh, Braak H (2006) Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm Suppl: 309-319.
20. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, et al. (2007) Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 27: 9220-9232.
21. Schnack C, Danzer KM, Hengerer B, Gillardon F, (2008) Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins. Neuroscience 154: 1450-1457.
22. Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, et al. (2009) Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther 15 (2): 157-182.
23. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, et al. (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64: 850-855.
24. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, et al. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240.
25. Lehnert S, Jesse S, Rist W, Steinacker P, Soininen H, et al. (2012) iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol 234: 499-505.
26. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, et al. (2008) Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8: 4357-4366.
27. Dubois B, Pillon B, (1997) Cognitive deficits in Parkinson's disease. J Neurol 244: 2-8.
28. Bothe M, Uttner I, Otto M, (2010) Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. Journal of Neural Transmission 117: 353-367.
29. Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, et al. (2008) Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract 62: 1581-1587.
30. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, et al. (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69: 1569-1579.
31. Potempa J, Korzus E, Travis J, (1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269: 15957-15960.
32. Lomas DA, Belorgey D, Mallya M, Miranda E, Kinghorn KJ, et al. (2005) Molecular mousetraps and the serpinopathies. Biochem Soc Trans 33: 321-330.
33. Gross V, Geiger T, Tran-Thi TA, Gauthier F, Heinrich PC, (1982) Biosynthesis and secretion of alpha 1-antitrypsin in primary cultures of rat hepatocytes. Characterization of differently glycosylated intracellular and extracellular forms. Eur J Biochem 129: 317-323.
34. Kleene R, Schachner M, (2004) Glycans and neural cell interactions. Nat Rev Neurosci 5: 195-208.
35. Liu F, Iqbal K, Grundke-Iqbal I, Gong CX, (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett 530: 209-214.
36. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Merkle RK, et al. (2002) Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett 512: 101-106.
37. Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, et al. (2009) Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev 29: 79-125.
38. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et al. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269.
39. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, et al. (2012) Phosphorylated a-Synuclein in Parkinson's Disease. Sci Transl Med 4: 121ra20.
40. Ross CA, Poirier MA, (2004) Protein aggregation and neurodegenerative disease. Nat Med 10Suppl: S10-17.
41. Crowther RA, Jakes R, Spillantini MG, Goedert M, (1998) Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436: 309-312.
42. Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM, (2008) Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol Med 14: 451-464.
43. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473.
44. Devlin GL, Chow MK, Howlett GJ, Bottomley SP, (2002) Acid Denaturation of alpha1-antitrypsin: characterization of a novel mechanism of serpin polymerization. J Mol Biol 324: 859-870.
45. Kok KF, Wahab PJ, Houwen RH, Drenth JP, de Man RA, et al. (2007) Heterozygous alpha-I antitrypsin deficiency as a co-factor in the development of chronic liver disease: a review. Neth J Med 65: 160-166.
46. Yamasaki M, Li W, Johnson DJ, Huntington JA, (2008) Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455: 1255-1258.
47. Crowther DC, (2002) Familial conformational diseases and dementias. Hum Mutat 20: 1-14.
48. Davis RL, Holohan PD, Shrimpton AE, Tatum AH, Daucher J, et al. (1999) Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 155: 1901-1913.
49. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
50. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, et al. (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58: 1803-1809.
51. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, et al. (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-1554.
52. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, et al. (2003) A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3: 36-44.
53. Tastet C, Lescuyer P, Diemer H, Luche S, van Dorsselaer A et al, (2003) A versatile electrophoresis system for the analysis of high- and low-molecular-weight proteins. Electrophoresis 24: 1787-1794.
54. Jahn O, Hesse D, Reinelt M, Kratzin HD, (2006) Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal Bioanal Chem 386: 92-103.
55. Jesse S, Steinacker P, Lehnert S, Sdzuj M, Cepek L, et al. (2010) A proteomic approach for the diagnosis of bacterial meningitis. PLoS One 5: e10079.
56. Werner H, Kuhlmann K, Shen S, Uecker M, Schardt A, et al. (2007) Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27: 7717-7730.
57. Reumann S, Babujee L, Ma C, Wienkoop S, Siemsen T, et al. (2007) Proteome analysis of Arabidopsis leaf peroxisomes reveals novel targeting peptides, metabolic pathways, and defense mechanisms. Plant Cell 19: 3170-3193.
58. Altman DG, Bland JM, (1994) Diagnostic tests. 1: Sensitivity and specificity. BMJ 308: 1552.